Illumina, Inc. $ILMN Stock Bought by Keybank National Association OH

Keybank National Association OH boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 376,809 shares of the life sciences company’s stock after purchasing an additional 5,682 shares during the period. Keybank National Association OH owned about 0.25% of Illumina worth $103,125,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Illumina in the 2nd quarter valued at about $3,374,423,000. Plato Investment Management Ltd bought a new position in Illumina during the second quarter worth about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Illumina during the second quarter worth about $30,501,000. Edmond DE Rothschild Holding S.A. bought a new position in Illumina during the second quarter worth about $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Illumina during the second quarter worth approximately $6,711,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ILMN. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a research report on Saturday. JPMorgan Chase & Co. decreased their target price on Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a report on Friday, October 30th. Canaccord Genuity Group boosted their target price on Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Argus increased their price target on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Finally, Piper Sandler raised their price target on Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, September 28th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $244.24.

Insider Activity at Illumina

In other news, Director Keith Meister sold 299,336 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the sale, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 1,601,541 shares of company stock valued at $354,755,291. 2.90% of the stock is currently owned by insiders.

Illumina Stock Performance

NASDAQ:ILMN opened at $214.91 on Wednesday. The company has a market cap of $32.49 billion, a price-to-earnings ratio of 42.05, a PEG ratio of 3.00 and a beta of 1.46. Illumina, Inc. has a fifty-two week low of $112.65 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The stock has a fifty day moving average price of $249.27 and a 200-day moving average price of $178.77.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned $1.34 earnings per share. As a group, equities analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.